Search
QiSelian Biotech Secures Initial Funding, Pioneering Personalized Cell Therapy and Anti-Aging Solutions
2025-04-18 /
Read about 0 minute
Author：小编
QiSelian Biotech has successfully concluded its inaugural funding round, exclusively financed by BioVeda Capital. The procured capital will be strategically allocated towards intensifying platform development and product innovation. The company stands at the forefront of personalized cell therapy and anti-aging, harnessing the power of induced pluripotent stem cell (iPSC) technology to pioneer autologous cell therapies, regenerative medicine, and groundbreaking health management solutions. This investment underscores the investors' strong belief in the potential of iPSC therapy and their unwavering commitment to advancing the biopharmaceutical landscape.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
